Skip to main content
. 2020 Aug 27;117(37):22992–23000. doi: 10.1073/pnas.2003621117

Fig. 3.

Fig. 3.

Contribution of complement and FcγRs to 3F6-hIgG1HEK–mediated protection against MRSA bloodstream infection. (A–C) Animals (BALB/c; n = 10 from 2 independent experiments) received control hIgG1, 3F6-hIgG1HEK, 3F6-hIgG1HEK-KA, or 3F6-hIgG1HEK-LALA before challenge with S. aureus MW2. Disease was assessed as described in Fig. 1. (D–F) Animals (BALB/c; n = 10 from 2 independent experiments) were treated with control hIgG1, 3F6-hIgG1HEK, or 3F6-hIgG1HEK-afu antibodies prior to challenge with S. aureus MW2. Disease was assessed as described in Fig. 1. Data are presented as mean ± SEM. Significant differences were identified with one-way ANOVA with Kruskal–Wallis test (**P < 0.01; *P < 0.05). One of two repeats is shown.